Merck & Co's Gefapixant Cuts Chronic Cough in Phase III
But Concerns Over Taste Side Effects
New data puts Merck & Co's P2X3 receptor antagonist ahead of the field but Bellus Health's rival in the class may benefit from issues over taste alteration with gefapixant.
You may also be interested in...
Respivant will be Roivant's 13th "vant," focused on developing what was Patara Pharma's mast cell stimulator for chronic cough in patients with idiopathic pulmonary fibrosis. Former Patara CEO Bill Gerhart will lead the firm.
A candidate for chronic cough is one of the assets Merck & Co. will get by buying P2X3 inhibitor specialist Afferent Pharmaceuticals Inc, a US-based biotech focusing on chronic pain therapies caused when certain nerves become hypersensitive.
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.